Aeovian Pharmaceuticals
CompanyUnited States
Aeovian Pharmaceuticals develops one asset, in phase 1 (AV078 in tuberous sclerosis complex). Mostly small molecule acting on autophagy, mTOR signalling and MTOR; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- Raised
- US$173.8m
- 1
- Trial
- 0
- Signals
Pipeline
1CNS-penetrant selective inhibition of mTORC1.
Phase 1, Small molecule, Autophagy, mTOR signalling, tuberous sclerosis complex
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Funding rounds and grants4
- People14
- Signals1
- Similar companies6